Entero Therapeutics, Inc. (NASDAQ:ENTO) Sees Large Growth in Short Interest

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 393,700 shares, a growth of 666.0% from the July 31st total of 51,400 shares. Approximately 12.5% of the company’s shares are short sold. Based on an average trading volume of 544,900 shares, the days-to-cover ratio is presently 0.7 days.

Entero Therapeutics Trading Up 0.9 %

Shares of Entero Therapeutics stock opened at $0.44 on Wednesday. The stock’s 50-day simple moving average is $0.88. Entero Therapeutics has a 1-year low of $0.19 and a 1-year high of $22.20. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.21 and a quick ratio of 1.21.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.